AMGN on XNAS, Health Care, Amgen Inc, job postings
Measures activity, not value. Not investment advice.
Profit rose 34% to $9.4B in 12 months as the stock gained 30%, while revenue grew 8.2%.
WatchCapital spending up 35% to $587M last quarter, direction unclear
BadVisa hiring applications down 8.4%, to 381 from 416 in 12 months
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
Industry
Biological products, (no diagnostic substances) (Health Care)
expected around 2 Feb 2027 (an estimate: a year ago it reported on 3 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $10.4B, net income $3.9B.
31 Dec 2021RevenueNet incomeNet losstallest bar $10.4B30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$10.4B
$3.9B
30 Jun 2026
$10.1B
$2.4B
31 Mar 2026
$8.6B
$1.8B
31 Dec 2025
$9.9B
$1.3B
30 Sep 2025
$9.6B
$3.2B
30 Jun 2025
$9.2B
$1.4B
31 Mar 2025
$8.1B
$1.7B
31 Dec 2024
$9.1B
$627.0M
30 Sep 2024
$8.5B
$2.8B
30 Jun 2024
$8.4B
$746.0M
31 Mar 2024
$7.4B
-$113.0M
31 Dec 2023
$8.2B
$767.0M
30 Sep 2023
$6.9B
$1.7B
30 Jun 2023
$7.0B
$1.4B
31 Mar 2023
$6.1B
$2.8B
31 Dec 2022
$6.8B
$1.6B
30 Sep 2022
$6.7B
$2.1B
30 Jun 2022
$6.6B
$1.3B
31 Mar 2022
$6.2B
$1.5B
31 Dec 2021
$6.8B
$1.9B
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$38.9B
$36.0B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+8.2%
+8.2%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$9.4B
$7.0B
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$17.25
$12.94
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
70.9%
66.2%
70.4%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
32.4%
24.1%
-98.6%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
24.1%
19.5%
-47.8%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
78.4%
-58.2%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$9.6B
$11.5B
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$13.2B
$9.4B
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$54.0B
$54.6B
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
$40.8B
$45.1B
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
3.8
0.0
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$26.53
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
25.1
21.6
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
6.1
8.0
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
7.1
6.0
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
16.4
2.0
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
2.2%
1.6%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Insider Buy/Sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
–
No data for this company
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+4.5%
3,228 13F filers vs 3,090
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
81%
439.0M shares held by 13F filers (30 Sep 2026) of 540.9M outstanding (29 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.3%
12.6M shares sold short (30 Oct 2026) of 540.9M outstanding (29 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
5.0
12.6M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-5.9%
13.4M shares sold short in the report before, 12.6M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
54%
54% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 55%
Open jobs iJob postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.
–
We do not track this company's careers site yet.
Open jobs change iHow the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.
–
We do not track this company's careers site yet.
Employees iTotal staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.
–
No headcount in its annual reports in our data.
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
-8.4%
381 vs 416 applications
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+8.5%
$10.4B vs $9.6B (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
+35%
$587.0M vs $436.0M (quarter ended 30 Sep 2026)
Federal contracts iMoney the US government committed to the company in contracts and grants over the last 12 months.
$2.3M
the 12 months before: $0
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$13.3M
4 quarters, $
Layoff notices iWorkers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).
–
No data for this company
News (7d) iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
65
65 articles in the last 7 days; its usual week has 8.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
7.6×
65 articles in the last 7 days; its usual week has 8.5.
Price $435.64 on 20 Nov 2026, +30% over 12 months (12-month range $313.85 to $478.48)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $25.7M in the last 12 months (the 12 months before: -$28.6M).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 372 published in the last 12 months, -12% on the 12 months before.Revenue per quarter. Revenue $10.4B in the latest quarter, +8.5% on a year earlier.Capital spending per quarter. Capital spending $587.0M in the latest quarter, +35% on a year earlier.Institutional holders (13F filers). 3,228 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.Federal obligations. Federal obligations: $0 published in the last 12 months, -100% on the 12 months before.Lobbying spend. Lobbying spend: $13.3M published in the last 12 months, -5.4% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: workers in warn layoff notices.
Quarter ended 31 Dec 2021: $6.8B; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $6.2B, +5.7% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $6.6B, +1.0% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $6.7B, -0.8% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $6.8B, -0.1% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $6.1B, -2.1% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $7.0B, +5.9% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $6.9B, +3.8% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $8.2B, +20% on a year earlier; public on 15 Feb 2024
Quarter ended 31 Mar 2024: $7.4B, +22% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $8.4B, +20% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $8.5B, +23% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $9.1B, +11% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $8.1B, +9.4% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $9.2B, +9.4% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $9.6B, +12% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $9.9B, +8.6% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $8.6B, +5.8% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $10.1B, +9.5% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $10.4B, +8.5% on a year earlier; public on 5 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $287.0M, +66% on a year earlier; public on 17 Feb 2022
Quarter ended 31 Mar 2022: $190.0M, +14% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $246.0M, +33% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $160.0M, -34% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $340.0M, +18% on a year earlier; public on 10 Feb 2023
Quarter ended 31 Mar 2023: $344.0M, +81% on a year earlier; public on 29 Apr 2023
Quarter ended 30 Jun 2023: $271.0M, +10% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $248.0M, +55% on a year earlier; public on 1 Nov 2023
Quarter ended 31 Dec 2023: $249.0M, -27% on a year earlier; public on 15 Feb 2024
Quarter ended 31 Mar 2024: $230.0M, -33% on a year earlier; public on 4 May 2024
Quarter ended 30 Jun 2024: $238.0M, -12% on a year earlier; public on 8 Aug 2024
Quarter ended 30 Sep 2024: $257.0M, +3.6% on a year earlier; public on 1 Nov 2024
Quarter ended 31 Dec 2024: $371.0M, +49% on a year earlier; public on 15 Feb 2025
Quarter ended 31 Mar 2025: $411.0M, +79% on a year earlier; public on 3 May 2025
Quarter ended 30 Jun 2025: $369.0M, +55% on a year earlier; public on 7 Aug 2025
Quarter ended 30 Sep 2025: $436.0M, +70% on a year earlier; public on 6 Nov 2025
Quarter ended 31 Dec 2025: $642.0M, +73% on a year earlier; public on 14 Feb 2026
Quarter ended 31 Mar 2026: $712.0M, +73% on a year earlier; public on 2 May 2026
Quarter ended 30 Jun 2026: $513.0M, +39% on a year earlier; public on 6 Aug 2026
Quarter ended 30 Sep 2026: $587.0M, +35% on a year earlier; public on 5 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 2,019; public on 14 Feb 2022
31 Mar 2022 report: 2,173; public on 16 May 2022
30 Jun 2022 report: 2,194; public on 15 Aug 2022
30 Sep 2022 report: 2,117; public on 14 Nov 2022
31 Dec 2022 report: 2,274; public on 14 Feb 2023
31 Mar 2023 report: 2,260; public on 15 May 2023
30 Jun 2023 report: 2,187; public on 14 Aug 2023
30 Sep 2023 report: 2,305; public on 14 Nov 2023
31 Dec 2023 report: 2,499; public on 14 Feb 2024
31 Mar 2024 report: 2,563; public on 15 May 2024
30 Jun 2024 report: 2,630; public on 14 Aug 2024
30 Sep 2024 report: 2,660; public on 14 Nov 2024
31 Dec 2024 report: 2,669; public on 14 Feb 2025
31 Mar 2025 report: 2,788; public on 15 May 2025
30 Jun 2025 report: 2,720; public on 14 Aug 2025
30 Sep 2025 report: 2,671; public on 14 Nov 2025
31 Dec 2025 report: 2,936; public on 17 Feb 2026
31 Mar 2026 report: 3,044; public on 15 May 2026
30 Jun 2026 report: 3,090; public on 14 Aug 2026
30 Sep 2026 report: 3,228; public on 16 Nov 2026
Federal obligations
Month from 1 Feb 2022: $2.2M published
Month from 1 Jul 2022: $475K published
Month from 1 Oct 2022: $290.1M published
Month from 1 Dec 2022: $0 published
Month from 1 Mar 2023: $0 published
Month from 1 Aug 2023: $7.3M published
Month from 1 Sep 2023: $205.0M published
Month from 1 Oct 2023: $129K published
Month from 1 May 2024: $0 published
Month from 1 Sep 2025: $2.3M published
Month from 1 Jun 2026: $0 published
Lobbying spend
Quarter from 1 Jan 2022: $2.8M published
Quarter from 1 Apr 2022: $3.1M published
Quarter from 1 Jul 2022: $2.4M published
Quarter from 1 Oct 2022: $3.5M published
Quarter from 1 Jan 2023: $2.5M published
Quarter from 1 Apr 2023: $3.1M published
Quarter from 1 Jul 2023: $2.3M published
Quarter from 1 Oct 2023: $3.3M published
Quarter from 1 Jan 2024: $3.9M published
Quarter from 1 Apr 2024: $3.7M published
Quarter from 1 Jul 2024: $3.1M published
Quarter from 1 Oct 2024: $3.1M published
Quarter from 1 Jan 2025: $3.1M published
Quarter from 1 Apr 2025: $4.0M published
Quarter from 1 Jul 2025: $3.0M published
Quarter from 1 Oct 2025: $4.0M published
Quarter from 1 Jan 2026: $4.0M published
Quarter from 1 Apr 2026: $3.0M published
Quarter from 1 Jul 2026: $2.8M published
Quarter from 1 Oct 2026: $3.5M published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $587.0M (30 Sep 2026), 1.4× its normal quarter; higher than 97% of its own history.
Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response
$21.5Mup to $33.3M
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF ROMIPLOSTIM FOR TREATMENT OF HEMATOPOIETIC SUBSYNDROME-ACUTE RADIATION SYNDROME (HS-ARS) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT) AND A DRUG DELIVERY DEVICE FEASIBILITY PROJECT WITH AN OPTION TO
Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response
$154.4Mup to $154.4M
IGF::OT::IGF RTOR NUMBER: RTOR-CSF-0005 ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION
Department of Health and Human ServicesOffice of Assistant Secretary for Preparedness and Response
IGF::OT::IGF FOR OTHER FUNCTIONS PROJECT: ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION (RTOR-CSF-0003)
In 12 months: 3 director or officer changes, 1 agreement ended, 1 major agreement, 1 cybersecurity incident. Results releases and routine reports are left out.
Reported lobbying spend: $3.5M in Q3 2026, $2.8M in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Two or more unrelated kinds of records unusual within 30 days
2 Sep 2025confirmed
Confirmed across sources Attention and Hiring and Filings + Financials
Amgen(AMGN): spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year; it also had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year; and it drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year. Three unrelated kinds of activity within 33 days.
Financials: Quarterly capital spending jump, became public on 7 Aug 2025
Hiring: H-1B/E-3 applications change, became public on 31 Aug 2025
Attention: Wikipedia attention spike, became public on 9 Sep 2025
The quarter ended 30 Jun 2025 against the 8 quarters before it.
this quarterearliernormal: $253.0MSee the evidence (3 changes)
Financials: Quarterly capital spending jump became public on 7 Aug 2025
Amgen spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.
This period
$369.0M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+4.6
Same quarter last year
$238.0M
History used
3,378 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $253.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Hiring: H-1B/E-3 applications change became public on 31 Aug 2025
Amgen had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.
This period
47 (June 2025)
Normal month (median of 5 earlier)
20
Typical spread (median absolute deviation)
2
How far from its usual level
+9.0
Same month last year
22
History used
2,099 days
June 20255 earlier monthsnormal: 20
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
Attention: Wikipedia attention spike became public on 9 Sep 2025
Amgen drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year.
This period
5,703 (the week of 1 Sep 2025)
Normal week (median of 26 earlier)
2,887
Typical spread (median absolute deviation)
203
How far from its usual level
+9.4
Same week last year
3,140
History used
2,441 days
the week of 1 Sep 202526 earlier weeksnormal: 2,887
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
6 May 2025confirmed
Confirmed across sources Filings + Financials and Short interest and volume
Amgen(AMGN): had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year, while it spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.
Short interest and volume: Short interest spike, became public on 10 Apr 2025
Short interest and volume: Short interest spike, became public on 26 Apr 2025
Financials: Quarterly capital spending jump, became public on 6 May 2025
Short interest and volume: Short interest spike, became public on 10 May 2025
The 15 Apr 2025 report against the 24 reports before it.
this reportearliernormal: 9.8MSee the evidence (4 changes)
Short interest and volume: Short interest spike became public on 10 Apr 2025
Amgen had 14.1M shares sold short in the 31 Mar 2025 report, 1.3× the same report last year.
This period
14.1M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
787K
How far from its usual level
+3.7
Same report last year
10.5M
History used
2,649 days
the 31 Mar 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Amgen had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.
This period
14.5M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
819K
How far from its usual level
+3.9
Same report last year
10.1M
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 6 May 2025
Amgen spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.
This period
$411.0M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+6.2
Same quarter last year
$230.0M
History used
5,934 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $253.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 May 2025
Amgen had 14.6M shares sold short in the 30 Apr 2025 report, 1.5× the same report last year.
This period
14.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
906K
How far from its usual level
+3.6
Same report last year
9.7M
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
15 Mar 2022confirmed
Confirmed across sources Hiring and Filings + Financials and Short interest and volume
Amgen(AMGN): spent $287.0M on capital projects in the quarter ended 31 Dec 2021, 1.7× the same quarter last year; it also had 28 H-1B/E-3 visa applications certified in November 2021, 3.1× the same month last year; and it had 20.7M shares sold short in the 14 Apr 2022 report, 1.9× the same report last year. Three unrelated kinds of activity within 126 days.
Financials: Quarterly capital spending jump, became public on 22 Feb 2022
Short interest and volume: Short interest spike, became public on 10 Mar 2022
Short interest and volume: Short interest spike, became public on 25 Mar 2022
Hiring: H-1B/E-3 applications change, became public on 31 Mar 2022
Short interest and volume: Short interest spike, became public on 12 Apr 2022
Short interest and volume: Short interest spike, became public on 27 Apr 2022
Short interest and volume: Short interest spike, became public on 11 May 2022
Short interest and volume: Short interest spike, became public on 25 May 2022
Short interest and volume: Short interest spike, became public on 10 Jun 2022
Short interest and volume: Short interest spike, became public on 28 Jun 2022
The quarter ended 31 Dec 2021 against the 8 quarters before it.
this quarterearliernormal: $169.5MSee the evidence (10 changes)
Financials: Quarterly capital spending jump became public on 22 Feb 2022
Amgen spent $287.0M on capital projects in the quarter ended 31 Dec 2021, 1.7× the same quarter last year.
This period
$287.0M (the quarter ended 31 Dec 2021)
Normal quarter (median of 8 earlier)
$169.5M
Typical spread (median absolute deviation)
$17.0M
How far from its usual level
+4.7
Same quarter last year
$173.0M
History used
4,748 days
the quarter ended 31 Dec 20218 earlier quartersnormal: $169.5M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 Mar 2022
Amgen had 26.6M shares sold short in the 28 Feb 2022 report, 3.3× the same report last year.
This period
26.6M (the 28 Feb 2022 report)
Normal report (median of 24 earlier)
11.2M
Typical spread (median absolute deviation)
526K
How far from its usual level
+13.7
Same report last year
8.1M
History used
1,522 days
the 28 Feb 2022 report24 earlier reportsnormal: 11.2M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 Mar 2022
Amgen had 24.5M shares sold short in the 15 Mar 2022 report, 2.5× the same report last year.
This period
24.5M (the 15 Mar 2022 report)
Normal report (median of 24 earlier)
11.3M
Typical spread (median absolute deviation)
470K
How far from its usual level
+11.6
Same report last year
9.9M
History used
1,537 days
the 15 Mar 2022 report24 earlier reportsnormal: 11.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Hiring: H-1B/E-3 applications change became public on 31 Mar 2022
Amgen had 28 H-1B/E-3 visa applications certified in November 2021, 3.1× the same month last year.
This period
28 (November 2021)
Normal month (median of 2 earlier)
11
Typical spread (median absolute deviation)
2
How far from its usual level
+5.7
Same month last year
9
History used
791 days
November 20212 earlier monthsnormal: 11
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
Short interest and volume: Short interest spike became public on 12 Apr 2022
Amgen had 22.5M shares sold short in the 31 Mar 2022 report, 2.0× the same report last year.
This period
22.5M (the 31 Mar 2022 report)
Normal report (median of 24 earlier)
11.4M
Typical spread (median absolute deviation)
414K
How far from its usual level
+9.8
Same report last year
11.4M
History used
1,553 days
the 31 Mar 2022 report24 earlier reportsnormal: 11.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 27 Apr 2022
Amgen had 20.7M shares sold short in the 14 Apr 2022 report, 1.9× the same report last year.
This period
20.7M (the 14 Apr 2022 report)
Normal report (median of 24 earlier)
11.4M
Typical spread (median absolute deviation)
414K
How far from its usual level
+8.2
Same report last year
11.0M
History used
1,567 days
the 14 Apr 2022 report24 earlier reportsnormal: 11.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 11 May 2022
Amgen had 19.9M shares sold short in the 29 Apr 2022 report, 1.9× the same report last year.
This period
19.9M (the 29 Apr 2022 report)
Normal report (median of 24 earlier)
11.4M
Typical spread (median absolute deviation)
457K
How far from its usual level
+7.4
Same report last year
10.6M
History used
1,582 days
the 29 Apr 2022 report24 earlier reportsnormal: 11.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 25 May 2022
Amgen had 18.9M shares sold short in the 13 May 2022 report, 1.6× the same report last year.
This period
18.9M (the 13 May 2022 report)
Normal report (median of 24 earlier)
11.5M
Typical spread (median absolute deviation)
620K
How far from its usual level
+6.4
Same report last year
11.5M
History used
1,596 days
the 13 May 2022 report24 earlier reportsnormal: 11.5M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Jun 2022
Amgen had 20.3M shares sold short in the 31 May 2022 report, 2.0× the same report last year.
This period
20.3M (the 31 May 2022 report)
Normal report (median of 24 earlier)
11.6M
Typical spread (median absolute deviation)
702K
How far from its usual level
+7.5
Same report last year
10.0M
History used
1,614 days
the 31 May 2022 report24 earlier reportsnormal: 11.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 28 Jun 2022
Amgen had 18.5M shares sold short in the 15 Jun 2022 report, 1.8× the same report last year.
This period
18.5M (the 15 Jun 2022 report)
Normal report (median of 24 earlier)
11.6M
Typical spread (median absolute deviation)
1.1M
How far from its usual level
+4.2
Same report last year
10.0M
History used
1,629 days
the 15 Jun 2022 report24 earlier reportsnormal: 11.6M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
26 Oct 2026Filings change
filed a director or officer change (8-K item 5.02), its first in 90 days.
Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.
spent $642.0M on capital projects in the quarter ended 31 Dec 2025, 1.7× the same quarter last year.
Same quarter last year: $371.0M; its normal quarter is $313.0M.
See the evidence
This period
$642.0M (the quarter ended 31 Dec 2025)
Normal quarter (median of 8 earlier)
$313.0M
Typical spread (median absolute deviation)
$69.5M
How far from its usual level
+3.2
Same quarter last year
$371.0M
History used
6,209 days
the quarter ended 31 Dec 20258 earlier quartersnormal: $313.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $436.0M on capital projects in the quarter ended 30 Sep 2025, 1.7× the same quarter last year.
Same quarter last year: $257.0M; its normal quarter is $253.0M.
See the evidence
This period
$436.0M (the quarter ended 30 Sep 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$19.0M
How far from its usual level
+6.5
Same quarter last year
$257.0M
History used
3,470 days
the quarter ended 30 Sep 20258 earlier quartersnormal: $253.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year.
Same week last year: 3,140; its normal week is 2,887.
See the evidence
This period
5,703 (the week of 1 Sep 2025)
Normal week (median of 26 earlier)
2,887
Typical spread (median absolute deviation)
203
How far from its usual level
+9.4
Same week last year
3,140
History used
2,441 days
the week of 1 Sep 202526 earlier weeksnormal: 2,887
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year; it also had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year; and it drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year. Three unrelated kinds of activity within 33 days.
See the evidence (3 changes)
Financials: Quarterly capital spending jump became public on 7 Aug 2025
Amgen spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.
This period
$369.0M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+4.6
Same quarter last year
$238.0M
History used
3,378 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $253.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Hiring: H-1B/E-3 applications change became public on 31 Aug 2025
Amgen had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.
This period
47 (June 2025)
Normal month (median of 5 earlier)
20
Typical spread (median absolute deviation)
2
How far from its usual level
+9.0
Same month last year
22
History used
2,099 days
June 20255 earlier monthsnormal: 20
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
Attention: Wikipedia attention spike became public on 9 Sep 2025
Amgen drew 5,703 Wikipedia page views in the week of 1 Sep 2025, 1.8× the same week last year.
This period
5,703 (the week of 1 Sep 2025)
Normal week (median of 26 earlier)
2,887
Typical spread (median absolute deviation)
203
How far from its usual level
+9.4
Same week last year
3,140
History used
2,441 days
the week of 1 Sep 202526 earlier weeksnormal: 2,887
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
31 Aug 2025Hiring change
had 47 H-1B/E-3 visa applications certified in June 2025, 2.1× the same month last year.
Same month last year: 22; its normal month is 20.
See the evidence
This period
47 (June 2025)
Normal month (median of 5 earlier)
20
Typical spread (median absolute deviation)
2
How far from its usual level
+9.0
Same month last year
22
History used
2,099 days
June 20255 earlier monthsnormal: 20
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 9+ earlier periods, 365+ days of history and a value of at least 20.
spent $369.0M on capital projects in the quarter ended 30 Jun 2025, 1.6× the same quarter last year.
Same quarter last year: $238.0M; its normal quarter is $253.0M.
See the evidence
This period
$369.0M (the quarter ended 30 Jun 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+4.6
Same quarter last year
$238.0M
History used
3,378 days
the quarter ended 30 Jun 20258 earlier quartersnormal: $253.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 14.6M shares sold short in the 30 Apr 2025 report, 1.5× the same report last year.
Same report last year: 9.7M; its normal report is 9.8M.
See the evidence
This period
14.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
906K
How far from its usual level
+3.6
Same report last year
9.7M
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year, while it spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year. Two unrelated kinds of activity within 28 days.
See the evidence (4 changes)
Short interest and volume: Short interest spike became public on 10 Apr 2025
Amgen had 14.1M shares sold short in the 31 Mar 2025 report, 1.3× the same report last year.
This period
14.1M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
787K
How far from its usual level
+3.7
Same report last year
10.5M
History used
2,649 days
the 31 Mar 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Apr 2025
Amgen had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.
This period
14.5M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
819K
How far from its usual level
+3.9
Same report last year
10.1M
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly capital spending jump became public on 6 May 2025
Amgen spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.
This period
$411.0M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+6.2
Same quarter last year
$230.0M
History used
5,934 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $253.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Short interest and volume: Short interest spike became public on 10 May 2025
Amgen had 14.6M shares sold short in the 30 Apr 2025 report, 1.5× the same report last year.
This period
14.6M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
906K
How far from its usual level
+3.6
Same report last year
9.7M
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
6 May 2025Financials change
spent $411.0M on capital projects in the quarter ended 31 Mar 2025, 1.8× the same quarter last year.
Same quarter last year: $230.0M; its normal quarter is $253.0M.
See the evidence
This period
$411.0M (the quarter ended 31 Mar 2025)
Normal quarter (median of 8 earlier)
$253.0M
Typical spread (median absolute deviation)
$16.5M
How far from its usual level
+6.2
Same quarter last year
$230.0M
History used
5,934 days
the quarter ended 31 Mar 20258 earlier quartersnormal: $253.0M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
had 14.5M shares sold short in the 15 Apr 2025 report, 1.4× the same report last year.
Same report last year: 10.1M; its normal report is 9.8M.
See the evidence
This period
14.5M (the 15 Apr 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
819K
How far from its usual level
+3.9
Same report last year
10.1M
History used
2,664 days
the 15 Apr 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 14.1M shares sold short in the 31 Mar 2025 report, 1.3× the same report last year.
Same report last year: 10.5M; its normal report is 9.8M.
See the evidence
This period
14.1M (the 31 Mar 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
787K
How far from its usual level
+3.7
Same report last year
10.5M
History used
2,649 days
the 31 Mar 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 15.1M shares sold short in the 14 Mar 2025 report, 1.4× the same report last year.
Same report last year: 11.1M; its normal report is 9.8M.
See the evidence
This period
15.1M (the 14 Mar 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
787K
How far from its usual level
+4.5
Same report last year
11.1M
History used
2,632 days
the 14 Mar 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.2M shares sold short in the 28 Feb 2025 report, 1.5× the same report last year.
Same report last year: 11.0M; its normal report is 9.8M.
See the evidence
This period
16.2M (the 28 Feb 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
787K
How far from its usual level
+5.4
Same report last year
11.0M
History used
2,618 days
the 28 Feb 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 16.1M shares sold short in the 14 Feb 2025 report, 1.4× the same report last year.
Same report last year: 11.1M; its normal report is 9.8M.
See the evidence
This period
16.1M (the 14 Feb 2025 report)
Normal report (median of 24 earlier)
9.8M
Typical spread (median absolute deviation)
787K
How far from its usual level
+5.4
Same report last year
11.1M
History used
2,604 days
the 14 Feb 2025 report24 earlier reportsnormal: 9.8M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
drew 5,235 Wikipedia page views in the week of 9 Sep 2024, 1.9× the same week last year.
Same week last year: 2,813; its normal week is 3,127.
See the evidence
This period
5,235 (the week of 9 Sep 2024)
Normal week (median of 26 earlier)
3,127
Typical spread (median absolute deviation)
159
How far from its usual level
+6.7
Same week last year
2,813
History used
2,084 days
the week of 9 Sep 202426 earlier weeksnormal: 3,127
Fires when the period is at least 5.0 robust standard deviations above the company's own median, with 20+ earlier periods, 365+ days of history and a value of at least 5,000.
had 11.0M shares sold short in the 29 Feb 2024 report, 1.5× the same report last year.
Same report last year: 7.4M; its normal report is 7.4M.
See the evidence
This period
11.0M (the 29 Feb 2024 report)
Normal report (median of 24 earlier)
7.4M
Typical spread (median absolute deviation)
665K
How far from its usual level
+3.7
Same report last year
7.4M
History used
2,253 days
the 29 Feb 2024 report24 earlier reportsnormal: 7.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 11.1M shares sold short in the 15 Feb 2024 report, 1.5× the same report last year.
Same report last year: 7.4M; its normal report is 7.4M.
See the evidence
This period
11.1M (the 15 Feb 2024 report)
Normal report (median of 24 earlier)
7.4M
Typical spread (median absolute deviation)
607K
How far from its usual level
+4.1
Same report last year
7.4M
History used
2,239 days
the 15 Feb 2024 report24 earlier reportsnormal: 7.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Showing the newest 40 of 169 entries; narrow the window or the kind of data to see older ones.
Not listed: 220 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000318154
Ticker
AMGN
Domain
amgen.com
Employer name
Amgen Incorporated (1 unverified)
Hq location
CA|THOUSAND OAKS|91320 (1 unverified)
Lobbying client
akin gump on behalf of amgen, amgen, amgen inc fka horizon therapeutics usa, capitol counsel llc on behalf of amgen and 2 more
Name
Amgen Canada Inc, Amgen (Europe) GmbH, Amgen Fremont Inc, Amgen Global Finance B.V and 35 more
Uei
D92HARF1LKA9
Wikidata
Q470517
Wikipedia
Amgen
DOL H-1B labor condition applications and PERM certifications1853 data points1 Oct 2019 to 28 Sep 2026
Federal lobbying disclosures (LDA)198 records, 279 data points30 Dec 1899 to 30 Sep 2026
SEC Form 13F institutional holdings8 records, 481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)163 records28 Jan 2016 to 3 Nov 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1203 data points31 Dec 2006 to 29 Oct 2026
SEC Form 4 insider transactions82 records, 292 data points4 Mar 2016 to 13 Aug 2026
FINRA short interest (twice monthly)636 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards7 records, 90 data points30 Sep 2009 to 2 Jun 2026
Wikipedia pageviews2882 data points1 Jan 2019 to 21 Nov 2026